Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Molecular Cancer
Published in: Molecular Cancer 1/2009

Open Access 01-12-2009 | Research

Expression levels of HMGA2 in adipocytic tumors correlate with morphologic and cytogenetic subgroups

Authors: Hammurabi Bartuma, Ioannis Panagopoulos, Anna Collin, Domenico Trombetta, Henryk A Domanski, Nils Mandahl, Fredrik Mertens

Published in: Molecular Cancer | Issue 1/2009

Login to get access

Abstract

Background

The HMGA2 gene encodes a protein that alters chromatin structure. Deregulation, typically through chromosomal rearrangements, of HMGA2 has an important role in the development of several mesenchymal neoplasms. These rearrangements result in the expression of a truncated protein lacking the acidic C-terminus, a fusion protein consisting of the AT-hook domains encoded by exons 1–3 and parts from another gene, or a full-length protein; loss of binding sites for regulatory microRNA molecules from the 3' untranslated region (UTR) of HMGA2 has been suggested to be a common denominator.

Methods

Seventy adipocytic tumors, representing different morphologic and cytogenetic subgroups, were analyzed by qRT-PCR to study the expression status of HMGA2; 18 of these tumors were further examined by PCR to search for mutations or deletions in the 3'UTR.

Results

Type (full-length or truncated) and level of expression varied with morphology and karyotype, with the highest levels in atypical lipomatous tumors and lipomas with rearrangements of 12q13-15 and the lowest in lipomas with 6p- or 13q-rearrangements, hibernomas, spindle cell lipomas and myxoid liposarcomas. All 18 examined tumors showed reduced or absent expression of the entire, or parts of, the 3'UTR, which was not due to mutations at the DNA level.

Conclusion

In adipocytic tumors with deregulated HMGA2 expression, the 3'UTR is consistently lost, either due to physical disruption of HMGA2 or a shift to production of shorter 3'UTR.
Appendix
Available only for authorised users
Literature
1.
Reeves R, Beckerbauer L: HMGI/Y proteins: flexible regulators of transcription and chromatin structure. Biochim Biophys Acta. 2001, 1519: 13-29.CrossRefPubMed
2.
Fusco A, Fedele M: Roles of HMGA proteins in cancer. Nat Rev Cancer. 2007, 7: 899-910. 10.1038/nrc2271.CrossRefPubMed
3.
Cleynen I, Ven Van de WJ: The HMGA proteins: a myriad of functions. Int J Oncol. 2008, 32: 289-305.PubMed
4.
Li O, Li J, Dröge P: DNA architectural factor and proto-oncogene HMGA2 regulates key developmental genes in pluripotent human embryonic stem cells. FEBS Lett. 2007, 581: 3533-3537. 10.1016/j.febslet.2007.06.072.CrossRefPubMed
5.
Zhou X, Benson KF, Ashar HR, Chada K: Mutation responsible for the mouse pygmy phenotype in the developmentally regulated factor HMGI-C. Nature. 1995, 376: 771-774. 10.1038/376771a0.CrossRefPubMed
6.
Battista S, Fidanza V, Fedele M, Klein-Szanto AJ, Outwater E, Brunner H, Santoro M, Croce CM, Fusco A: The expression of a truncated HMGI-C gene induces gigantism associated with lipomatosis. Cancer Res. 1999, 59: 4793-4797.PubMed
7.
Zaidi MR, Okada Y, Chada KK: Misexpression of full-length HMGA2 induces benign mesenchymal tumors in mice. Cancer Res. 2006, 66: 7453-7459. 10.1158/0008-5472.CAN-06-0931.CrossRefPubMed
8.
Ligon AH, Moore SD, Parisi MA, Mealiffe ME, Harris DJ, Ferguson HL, Quade BJ, Morton CC: Constitutional rearrangement of the architectural factor HMGA2: a novel human phenotype including overgrowth and lipomas. Am J Hum Genet. 2005, 76: 340-348. 10.1086/427565.PubMedCentralCrossRefPubMed
9.
Gattas GJ, Quade BJ, Nowak RA, Morton CC: HMGIC expression in human adult and fetal tissues and in uterine leiomyomata. Genes Chromosomes Cancer. 1999, 25: 316-322. 10.1002/(SICI)1098-2264(199908)25:4<316::AID-GCC2>3.0.CO;2-0.CrossRefPubMed
10.
Ashar HR, Fejzo MS, Tkachenko A, Zhou X, Fletcher JA, Weremowicz S, Morton CC, Chada K: Disruption of the architectural factor HMGI-C: DNA-binding AT hook motifs fused in lipomas to distinct transcriptional regulatory domains. Cell. 1995, 82: 57-65. 10.1016/0092-8674(95)90052-7.CrossRefPubMed
11.
Schoenmakers EF, Wanschura S, Mols R, Bullerdiek J, Van den Berghe H, Van de Ven WJ: Recurrent rearrangements in the high mobility group protein gene, HMGI-C, in benign mesenchymal tumours. Nat Genet. 1995, 10: 436-444. 10.1038/ng0895-436.CrossRefPubMed
12.
Geurts JM, Schoenmakers EF, Van de Ven WJ: Molecular characterization of a complex chromosomal rearrangement in a pleomorphic salivary gland adenoma involving the 3'-UTR of HMGIC. Cancer Genet Cytogenet. 1997, 95: 198-205. 10.1016/S0165-4608(96)00411-6.CrossRefPubMed
13.
Fedele M, Berlingieri MT, Scala S, Chiariotti L, Viglietto G, Rippel V, Bullerdiek J, Santoro M, Fusco A: Truncated and chimeric HMGI-C genes induce neoplastic transformation of NIH3T3 murine fibroblasts. Oncogene. 1998, 17: 413-418. 10.1038/sj.onc.1201952.CrossRefPubMed
14.
Klotzbücher M, Wasserfall A, Fuhrmann U: Misexpression of wild-type and truncated isoforms of the high-mobility group I proteins HMGI-C and HMGI(Y) in uterine leiomyomas. Am J Pathol. 1999, 155: 1535-1542.PubMedCentralCrossRefPubMed
15.
Borrmann L, Wilkening S, Bullerdiek J: The expression of HMGA genes is regulated by their 3'UTR. Oncogene. 2001, 20: 4537-4541. 10.1038/sj.onc.1204577.CrossRefPubMed
16.
Quade BJ, Weremowicz S, Neskey DM, Vanni R, Ladd C, Dal Cin P, Morton CC: Fusion transcripts involving HMGA2 are not a common molecular mechanism in uterine leiomyomata with rearrangements in 12q15. Caner Res. 2003, 63: 1351-1358.
17.
18.
Mayr C, Hemann MT, Bartel DP: Disrupting the pairing between let-7 and Hmga2 enhances oncogenic transformation. Science. 2007, 315: 1576-1579. 10.1126/science.1137999.PubMedCentralCrossRefPubMed
19.
Bartuma H, Hallor KH, Panagopoulos I, Collin A, Rydholm A, Gustafson P, Bauer HCF, Brosjö O, Domanski HA, Mandahl N, Mertens F: Assessment of the clinical and molecular impact of different cytogenetic subgroups in a series of 272 lipomas with abnormal karyotype. Genes Chromosomes Cancer. 2007, 46: 594-606. 10.1002/gcc.20445.CrossRefPubMed
20.
Mandahl N, Heim S, Arheden K, Rydholm A, Willén H, Mitelman F: Three major cytogenetic subgroups can be identified among chromosomally abnormal solitary lipomas. Hum Genet. 1988, 79: 203-208. 10.1007/BF00366238.CrossRefPubMed
21.
ISCN: An International System for Human Cytogenetic Nomenclature 2009. Edited by: Shaffer LG, Slovak ML, Campbell LJ. 2009, Basel, Switzerland: Karger, 138-
22.
Heim S, Mandahl N, Kristoffersson U, Mitelman F, Rööser B, Rydholm A, Willén H: Marker ring chromosome – a new cytogenetic abnormality characterizing lipogenic tumors?. Cancer Genet Cytogenet. 1987, 24: 319-326. 10.1016/0165-4608(87)90114-2.CrossRefPubMed
23.
Mandahl N, Höglund M, Mertens F, Rydholm A, Willén H, Brosjö O, Mitelman F: Cytogenetic aberrations in 188 benign and borderline adipose tissue tumors. Genes Chromosomes Cancer. 1994, 9: 207-215. 10.1002/gcc.2870090309.CrossRefPubMed
24.
Dahlén A, Debiec-Rychter M, Pedeutour F, Domanski HA, Höglund M, Bauer HC, Rydholm A, Sciot R, Mandahl N, Mertens F: Clustering of deletions on chromosome 13 in benign and low-malignant lipomatous tumors. Int J Cancer. 2003, 103: 616-623. 10.1002/ijc.10864.CrossRefPubMed
25.
Nilsson M, Mertens F, Höglund M, Mandahl N, Panagopoulos I: Truncation and fusion of HMGA2 in lipomas with rearrangements of 5q32-->q33 and 12q14-->q15. Cytogenet Genome Res. 2006, 112: 60-66. 10.1159/000087514.CrossRefPubMed
26.
Dahlén A, Mertens F, Rydholm A, Brosjö O, Wejde J, Mandahl N, Panagopoulos I: Fusion, disruption, and expression of HMGA2 in bone and soft tissue chondromas. Mod Pathol. 2003, 16: 1132-1140. 10.1097/01.MP.0000092954.42656.94.CrossRefPubMed
27.
Livak KJ, Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCTT Method. Methods. 2001, 25: 402-408. 10.1006/meth.2001.1262.CrossRefPubMed
28.
Petit MM, Mols R, Schoenmakers EF, Mandahl N, Ven Van de WJ: LPP, the preferred fusion partner gene of HMGIC in lipomas, is a novel member of the LIM protein gene family. Genomics. 1996, 36: 118-129. 10.1006/geno.1996.0432.CrossRefPubMed
29.
Ashar HR, Tkachenko A, Shah P, Chada K: HMGA2 is expressed in an allele-specific manner in human lipomas. Cancer Genet Cytogenet. 2003, 143: 160-168. 10.1016/S0165-4608(03)00037-2.CrossRefPubMed
30.
Crombez KR, Vanoirbeek EM, Ven Van de WJ, Petit MM: Transactivation functions of the tumor-specific HMGA2/LPP fusion protein are augmented by wild-type HMGA2. Mol Cancer Res. 2005, 3: 63-70. 10.1158/1541-7786.MCR-04-0181.CrossRefPubMed
31.
Von Ahsen I, Rogalla P, Bullerdiek J: Expression patterns of the LPP-HMGA2 fusion transcript in pulmonary chondroid hamartomas with t(3;12)(q27~28;q14~15). Cancer Genet Cytogenet. 2005, 163: 68-70. 10.1016/j.cancergencyto.2005.02.023.CrossRefPubMed
32.
Tallini G, Dal Cin P, Rhoden KJ, Chiapetta G, Manfioletti G, Giancotti V, Fusco A, Berghe Van den H, Sciot R: Expression of HMGI-C and HMGI(Y) in ordinary lipoma and atypical lipomatous tumors: immunohistochemical reactivity correlates with karyotypic alterations. Am J Pathol. 1997, 151: 37-43.PubMedCentralPubMed
33.
Tallini G, Vanni R, Manfioletti G, Kazmierczak B, Faa G, Pauwels P, Bullerdiek J, Giancotti V, Berghe Van den H, Dal Cin P: HMGI-C and HMGI(Y) immunoreactivity correlates with cytogenetic abnormalities in lipomas, pulmonary chondroid hamartomas, endometrial polyps, and uterine leiomyomas and is compatible with rearrangement of the HMGI-C and HMGI(Y) genes. Lab Invest. 2000, 80: 359-369.CrossRefPubMed
34.
Kazmierczak B, Dal Cin P, Wanschura S, Borrmann L, Fusco A, Berghe Van den H, Bullerdiek J: HMGIY is the target of 6p21.3 rearrangements in various benign mesenchymal tumors. Genes Chromosomes Cancer. 1998, 23: 279-285. 10.1002/(SICI)1098-2264(199812)23:4<279::AID-GCC1>3.0.CO;2-1.CrossRefPubMed
35.
Dal Cin P, Kools P, Sciot R, De Wever I, Van Damme B, Ven Van de W, Berghe Van den H: Cytogenetic and fluorescence in situ hybridization investigation of ring chromosomes characterizing a specific pathologic subgroup of adipose tissue tumors. Cancer Genet Cytogenet. 1993, 68: 85-90. 10.1016/0165-4608(93)90001-3.CrossRefPubMed
36.
Pedeutour F, Forus A, Coindre JM, Berner JM, Nicolo G, Michiels JF, Terrier P, Ranchere-Vince D, Collin F, Myklebost O, Turc-Carel C: Structure of the supernumerary ring and giant rod chromosomes in adipose tissue tumors. Genes Chromosomes Cancer. 1999, 24: 30-41. 10.1002/(SICI)1098-2264(199901)24:1<30::AID-GCC5>3.0.CO;2-P.CrossRefPubMed
37.
Gisselsson D, Höglund M, Mertens F, Mitelman F, Mandahl N: Chromosomal organization of amplified chromosome 12 sequences in mesenchymal tumors detected by fluorescence in situ hybridization. Genes Chromosomes Cancer. 1998, 23: 203-212. 10.1002/(SICI)1098-2264(199811)23:3<203::AID-GCC1>3.0.CO;2-5.CrossRefPubMed
38.
Heidenblad M, Hallor KH, Staaf J, Jönsson G, Borg A, Höglund M, Mertens F, Mandahl N: Genomic profiling of bone and soft tissue tumors with supernumerary ring chromosomes using tiling resolution bacterial artificial chromosome microarrays. Oncogene. 2006, 25: 7106-7116. 10.1038/sj.onc.1209693.CrossRefPubMed
39.
Fletcher CDM, Akerman M, Dal Cin P, de Wever I, Mandahl N, Mertens F, Mitelman F, Rosai J, Rydholm A, Sciot R, Tallini G, Berghe Van den H, Ven Van de W, Vanni R, Willén H: Correlation between clinicopathological features and karyotype in lipomatous tumors. A report of 178 cases from the Chromosomes and Morphology (CHAMP) Collaborative Study Group. Am J Pathol. 1996, 148: 623-630.PubMedCentralPubMed
40.
Sandberg AA: Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: lipoma. Cancer Genet Cytogenet. 2004, 150: 93-115. 10.1016/j.cancergencyto.2003.12.018.CrossRefPubMed
41.
Bassett MD, Schuetze SM, Disteche C, Norwood TH, Swisshelm K, Chen X, Bruckner J, Conrad EU, Rubin BP: Deep-seated, well differentiated lipomatous tumors of the chest wall and extremities: the role of cytogenetics in classification and prognostication. Cancer. 2005, 103: 409-416. 10.1002/cncr.20779.CrossRefPubMed
42.
Billing V, Mertens F, Domanski HA, Rydholm A: Deep-seated ordinary and atypical lipomas: histopathology, cytogenetics, clinical features, and outcome in 215 tumours of the extremity and trunk wall. J Bone Joint Surg Br. 2008, 90: 929-933. 10.1302/0301-620X.90B7.20348.CrossRefPubMed
43.
Italiano A, Cardot N, Dupré F, Monticelli I, Keslair F, Piche M, Mainguené C, Coindre JM, Pedeutour F: Gains and complex rearrangements of the 12q13-15 chromosomal region in ordinary lipomas: the "missing link" between lipomas and liposarcomas?. Int J Cancer. 2007, 121: 308-315. 10.1002/ijc.22685.CrossRefPubMed
44.
Italiano A, Bianchini L, Keslair F, Bonnafous S, Cardot-Leccia N, Coindre JM, Dumollard JM, Hofman P, Leroux A, Maniguené , Peyrottes I, Ranchere-Vince D, Terrier P, Tran A, Gual P, Pedeutour F: HMGA2 is the partner of MDM2 in well-differentiated and dedifferentiated liposarcomas whereas CDK4 belongs to a distinct inconsistent amplicon. Int J Cancer. 2008, 122: 2233-2241. 10.1002/ijc.23380.CrossRefPubMed
45.
Persson F, Olofsson A, Sjögren H, Chebbo N, Nilsson B, Stenman G, Åman P: Characterization of the 12q amplicons by high-resolution, oligonucleotide array CGH and expression analyses of a novel liposarcoma cell line. Cancer Lett. 2008, 260: 37-47. 10.1016/j.canlet.2007.10.032.CrossRefPubMed
46.
Sciot R, Akerman M, Dal Cin P, De Wever I, Fletcher CD, Mandahl N, Mertens F, Mitelman F, Rosai J, Rydholm A, Tallini G, Van den Berghe H, Vanni R, Willén H: Cytogenetic analysis of subcutaneous angiolipoma: further evidence supporting its difference from ordinary pure lipomas: a report of the CHAMP Study Group. Am J Surg Pathol. 1997, 21: 441-444. 10.1097/00000478-199704000-00010.CrossRefPubMed
47.
Cina SJ, Radentz SS, Smialek JE: A case of familial angiolipomatosis with Lisch nodules. Arch Pathol Lab Med. 1999, 123: 946-948.PubMed
48.
Ashar HR, Cherath L, Przybysz KM, Chada K: Genomic characterization of human HMGIC, a member of the accessory transcription factor family found at translocation breakpoints in lipomas. Genomics. 1996, 31: 207-214. 10.1006/geno.1996.0033.CrossRefPubMed
49.
Hebert C, Norris K, Scheper MA, Nikitakis N, Sauk JJ: High mobility group A2 is a target for miRNA-98 in head and neck squamous cell carcinoma. Mol Cancer. 2007, 6: 5-10.1186/1476-4598-6-5.PubMedCentralCrossRefPubMed
50.
Wang T, Zhang X, Obijuru L, Laser J, Aris V, Lee P, Mittal K, Soteropoulos P, Wei JJ: A micro-RNA signature associated with race, tumor size, and target gene activity in human uterine leiomyomas. Genes Chromosomes Cancer. 2007, 46: 336-347. 10.1002/gcc.20415.CrossRefPubMed
51.
Sandberg R, Neilson JR, Sarma A, Sharp PA, Burge CB: Proliferating cells express mRNAs with shortened 3' untranslated regions and fewer microRNA target sites. Science. 2008, 320: 1643-1647. 10.1126/science.1155390.PubMedCentralCrossRefPubMed
52.
Rogalla P, Drechsler K, Frey G, Hennig Y, Helmke B, Bonk U, Bullerdiek J: HMGI-C expression patterns in human tissues. Implications for the genesis of frequent mesenchymal tumors. Am J Pathol. 1996, 149: 775-779.PubMedCentralPubMed
53.
Weedon MN, Lettre G, Freathy RM, Lindgren CM, Voight BF, Perry JRB, Elliott KS, Hackett R, Guiducci C, Shields B, Zeggini E, Lango H, Lyssenko V, Timpson NJ, Burtt NP, Rayner NW, Saxena R, Ardlie K, Tobias JH, Ness AR, Ring SM, Palmer CN, Morris AD, Peltonen L, Salomaa V, Davey Smith G, Groop LC, Hattersley AT, McCarthy MI, Hirschhorn JN, Frayling TM: A common variant of HMGA2 is associated with adult and childhood height in the general population. Nat Genet. 2007, 39: 1245-1250. 10.1038/ng2121.PubMedCentralCrossRefPubMed
Metadata
Title
Expression levels of HMGA2 in adipocytic tumors correlate with morphologic and cytogenetic subgroups
Authors
Hammurabi Bartuma
Ioannis Panagopoulos
Anna Collin
Domenico Trombetta
Henryk A Domanski
Nils Mandahl
Fredrik Mertens
Publication date
01-12-2009
Publisher
BioMed Central
Published in
Molecular Cancer / Issue 1/2009
Electronic ISSN: 1476-4598
DOI
https://doi.org/10.1186/1476-4598-8-36

Other articles of this Issue 1/2009

Molecular Cancer 1/2009 Go to the issue

Research

Differential expression of apoptotic genes PDIA3 and MAP3K5 distinguishes between low- and high-risk prostate cancer

Research

siRNA-based targeting of antiapoptotic genes can reverse chemoresistance in P-glycoprotein expressing chondrosarcoma cells

Research

Identification of iGb3 and iGb4 in melanoma B16F10-Nex2 cells and the iNKT cell-mediated antitumor effect of dendritic cells primed with iGb3

Research

CpG methylation profiling in VHL related and VHL unrelated renal cell carcinoma

Research

A new synthetic protein, TAT-RH, inhibits tumor growth through the regulation of NFκB activity

Review

Senescence induction; a possible cancer therapy
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits